Business Wire

Phenom Study: First Benchmark of European 100 Uncovers Opportunities to Meet Job Candidates’ High Expectations

8.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Phenom, the global leader in Talent Experience Management (TXM), released its first-ever State of Candidate Experience Report — European Edition. The comprehensive audit, which assessed the top 100 European companies on the Fortune Global 500 list in three key areas of the talent journey — attraction, engagement and conversion —revealed there is significant room to improve the experience with personalisation and automation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608005302/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Inaugural European Edition: State of Candidate Experience Report Provides Recommendations for Improvements (Graphic: Business Wire)

Talent acquisition is now a business priority among the C-suite — especially across industries with high-volume hiring needs — such as healthcare, hospitality, manufacturing, retail and transportation. But instead of using personalisation and automation technology to effectively and efficiently scale hiring, the majority of European 100 companies are falling short.

The 2022 audit of European 100 career sites reveals:

  • Only 9% had an intuitive job search and application process
  • Only 10% sent applicants a satisfaction survey
  • Only 6% had a recruitment chatbot
  • 96% did not present job recommendations based on browsing history
  • 90% did not display recently viewed jobs
  • 68% lacked a job cart or favorites function to save jobs
  • 0% communicated application status beyond initial confirmation

How Companies Can Improve the Candidate Experience

Simplify search and apply. Requiring three or more clicks to apply for a job is a major roadblock for candidates. The longer it takes for a candidate to find and apply to a relevant job, the greater the chance they will abandon the process and look elsewhere. One recommendation is for companies to equip their career sites with the ability to provide relevant suggested jobs based on a candidate’s keywords, skills, experience and location.

Create hyper-personalisation. Candidates are used to superior tailored experiences in their consumer lives. If finding a job that matches what they want is difficult, they are quick to move on. Dynamic personalisation is one way companies can automatically match a candidate’s preferences, experience, skills and location with best-fit job openings — and surface content for candidates as they move through their own unique end-to-end talent journey across multiple channels.

Automate communication. Job seekers want to know where they stand in the screening and interview scheduling process. Failure to communicate status details jeopardises employer brand and acceptance rates. Using conversational AI chatbots, SMS and email campaigns are a few ways companies can automate individualised communications to keep job seekers engaged while differentiating their brand.

“Hiring, developing and retaining talent isn’t just an HR priority — it is a business priority. Companies must differentiate themselves by the experiences they provide to their candidates and their employees to sustain,” said Mahe Bayireddi, CEO and co-founder of Phenom. “This benchmark report of the European 100 provides industry-specific insights and actionable recommendations for using automation and personalisation to earn and keep top talent.”

How Automation Helps Talent Experiences

Automation enables a quick, efficient hiring process that serves up best-fit jobs to candidates — and best-fit candidates to recruiters — while optimising omnichannel communications that nurture talent communities. Not only do job seekers appreciate a streamlined, personalised experience, but with efficiency at the core, recruiters and hiring managers benefit from decreased time to fill and better long-term fits.

Employees are no exception. The same hyper-personalised candidate experience should extend to internal talent, who may be looking to move within their current company. By making relevant open roles and development opportunities visible, actionable and attainable, companies stand a better chance at retaining them. AI-powered talent marketplaces automate the process for an employee experience that unifies all key stakeholders: internal candidates, recruiters and hiring managers.

With this report, companies can learn how to make changes — large or small — to enhance the candidate experience and provide a measurable, positive impact on their businesses.

Download the full 2022 State of the Candidate European Edition report and rankings here. Also recently published, the sixth annual report auditing the Fortune 500 is available for download here. Organisations can request their own complimentary career site audit here.

To request a demo of Phenom TXM visit phenom.com.

About Phenom

Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, HR teams are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Talent Experience Management (TXM) platform seamlessly connects candidates, employees, recruiters, and managers — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.

Phenom was ranked among the fastest-growing technology companies in Deloitte Technology's Fast 500 for four years in a row, has been recognized in Business Intelligence Group's 2021 and 2022 Artificial Intelligence Excellence Awards and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.

Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.

For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Jannes Zwirner I jannes.zwirner@tonka-pr.com I +49.172.3650385
Julia Trzinski I julia.trzinski@tonka-pr.com I +49.179.6178513

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye